F&Guide "MKF500 Index Special Inclusion of SK Biopharm"

"Deemed to Have Significant Impact on the Domestic Stock Market"

[Asia Economy Reporter Minji Lee] FnGuide announced on the 13th that SK Biopharm, which attracted the largest subscription deposit in history and received intense market attention, will be specially included in the MKF500 index starting from the 18th.

The MKF500 index, developed by FnGuide in 2006, is a benchmark index that covers both the KOSPI and KOSDAQ markets. Domestic institutional investors use this index as a performance evaluation benchmark for funds such as the Employment Insurance Fund and Shinhan Life Insurance.

SK Biopharm's market capitalization based on the closing price on the listing day was 9.9457 trillion KRW, but as of the 12th, when the inclusion in the index was decided, the market capitalization increased by about 50% to 14.9578 trillion KRW. It ranks 23rd in market capitalization among companies listed on the KOSPI and KOSDAQ markets.

Upon inclusion in the MKF500 index, SK Biopharm will also be included in the MKF Large Cap Index, MKF Growth Index, MKF Pure Growth Index, MKF Large Cap Growth Index, MKF Large Cap Pure Growth Index, MKF Mid-Large Cap Growth Index, and MKF Mid-Large Cap Pure Growth Index.

FnGuide stated, "We decided to specially include SK Biopharm in the MKF500 index because we judged that its influence on the domestic stock market is significant," adding, "When an IPO of a company that has a large impact on the domestic stock market occurs, we will reflect it in a timely manner so that investors can trust and utilize it as an indicator for various investment strategies."